Patent ID: 9422368
Filing Date: 2016-08-23
CPC Classification: A61P,C07K

Claim Text:
1. A method of treating a malignant neoplasm comprising administering to a subject having a malignant neoplasm expressing human leukocytic antigen-E (HLA-E) an effective amount of an antibody binding human CD94/NKG2A receptor, said antibody comprising: (a) a CDR-L1 comprising SEQ ID NO:5; (b) a CDR-L2 comprising SEQ ID NO:6; (c) a CDR-L3 comprising SEQ ID NO:7; (d) a CDR-H1 comprising SEQ ID NO:8; (e) a CDR-H2 comprising SEQ ID NO:9; (f) a CDR-H3 comprising SEQ ID NO:10; (g) human VL and VH framework regions; and (h) a proline (P) residue at Kabat position 46 in the VL domain.